Welcome to our dedicated page for Lineage Cell The SEC filings (Ticker: LCTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lineage Cell Therapeutics, Inc. filings document the disclosures of a clinical-stage biotechnology company developing allogeneic cell therapies and cell transplant product candidates. The company’s reports and current-event filings cover financial results, business updates, pipeline developments, research collaborations, clinical-program milestones, and manufacturing progress involving programs such as OpRegen, OPC1, and ReSonance.
Regulatory filings also describe Lineage’s capital structure and financing activity, including common share offerings under shelf registration and at-the-market arrangements. Proxy materials cover board matters, executive compensation, equity awards, shareholder voting items, and governance disclosures, while 8-K filings record material events tied to collaborations, grant-related developments, operating results, and other corporate updates.
Lineage Cell Therapeutics, Inc. reported that Chief Financial Officer Jill Ann Howe received a grant of 1,050,000 employee stock options on March 5, 2026. These options carry a stated exercise price of $0.0000 per share, reflecting a compensatory award rather than an open-market purchase.
According to the terms, one quarter of the options will vest on March 5, 2027. The remaining three quarters will then vest in 36 equal monthly installments, contingent on the completion of each month of continuous employment. Following this grant, Howe’s directly held option position from this award totals 1,050,000 options.
Samuel George A. III reported acquisition or exercise transactions in this Form 4 filing.
Lineage Cell Therapeutics, Inc. reported that its General Counsel and Secretary, Samuel George A. III, received a grant of 900,000 employee stock options on March 5, 2026. These options were awarded at no purchase price at grant as part of his compensation.
According to the vesting terms, one quarter of the options will vest on March 5, 2027, and the remaining options will vest in 36 monthly installments after that date, contingent on continuous employment each month.
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell replacement therapies to treat serious conditions caused by loss or dysfunction of specific cell types, an approach it calls “Replace and Restore.” All programs are built on its proprietary AlloSCOPE manufacturing platform for scalable, off‑the‑shelf pluripotent cell-derived products.
The lead asset, OpRegen (RG6501), an allogeneic retinal pigment epithelial therapy for geographic atrophy secondary to dry age-related macular degeneration, is partnered worldwide with Roche and Genentech. Lineage received a $50.0 million upfront payment and a $5.0 million development milestone, and remains eligible for up to $615.0 million in additional milestones plus tiered double‑digit royalties.
Lineage’s wholly owned pipeline includes OPC1 for spinal cord injury, which has RMAT and Orphan Drug designations and is being evaluated in the DOSED clinical study using a novel delivery device, and ReSonance (ANP1) for hearing loss, supported by a collaboration with William Demant Invest funding up to $12 million in preclinical work. Additional earlier initiatives target Type 1 diabetes manufacturing scale (ILT1), a hypoimmune iPSC line (RND1), and photoreceptor replacement (PNC1). As of March 5, 2026, Lineage had 249,087,529 common shares outstanding.
Lineage Cell Therapeutics reported higher revenue but a much larger net loss for 2025 while extending its cash runway and advancing its cell therapy pipeline. Total revenues for the year ended December 31, 2025 were $14.6 million, up from $9.5 million in 2024, mainly from collaboration revenue with Roche and a new research collaboration with William Demant Invest.
Total operating expenses rose to $51.2 million, including a $14.8 million impairment of an intangible asset related to the VAC platform. A large non-cash fair value remeasurement expense of warrant liabilities contributed to other expense of $32.0 million, versus other income of $2.9 million in 2024. Net loss attributable to Lineage widened to $63.5 million, or $0.28 per share, compared to $18.6 million, or $0.09 per share.
As of December 31, 2025, cash, cash equivalents and marketable securities were $55.8 million. Together with approximately $5.4 million in warrant exercise proceeds in March 2026, management expects this to fund planned operations into the second quarter of 2028. Operationally, the company achieved its first OpRegen milestone under its collaboration with Roche and Genentech, reported positive 36‑month OpRegen Phase 1/2a data, demonstrated high-scale AlloSCOPE manufacturing, secured up to $12 million of planned ReSonance (ANP1) preclinical funding from William Demant Invest, and treated the first chronic spinal cord injury patient in the OPC1 DOSED study.
Culley Brian M reported multiple insider transaction types in a Form 4 filing for LCTX. The filing lists transactions totaling 75,369 shares at a weighted average price of $1.80 per share. Following the reported transactions, holdings were 253,385 shares.
Samuel George A. III reported multiple insider transaction types in a Form 4 filing for LCTX. The filing lists transactions totaling 14,652 shares at a weighted average price of $1.80 per share. Following the reported transactions, holdings were 33,565 shares.
Lineage Cell Therapeutics, Inc. reported an insider equity transaction by its President and CEO and Director, Brian M. Culley. On 12/19/2025, he earned 8,925 common shares upon vesting of restricted stock units that were granted on February 11, 2022, which were subject to performance conditions. These RSUs are settled in common shares on a one-for-one basis.
On the same date, 334 shares were withheld by the company at a price of $1.68 per share to cover statutory tax withholding obligations related to the vesting. After these transactions, Culley beneficially owned 222,135 common shares directly. The disclosure notes that this amount does not include unvested RSUs or shares that could be acquired through outstanding stock options.
Lineage Cell Therapeutics, Inc. reported an insider equity transaction by its General Counsel and Secretary, George A. Samuel III. On 12/19/2025, he acquired 1,735 common shares through the vesting of previously granted performance-based restricted stock units, which convert into common shares on a one-for-one basis. The company then withheld 65 shares at $1.68 per share to cover statutory tax obligations related to this vesting, with no shares sold on the open market.
Following these transactions, Samuel directly beneficially owned 27,490 common shares of Lineage Cell Therapeutics. The filing notes that this total does not include any unvested restricted stock units or shares that could be acquired through outstanding stock options that remained unexercised as of the report date.
Lineage Cell Therapeutics reported that it has withdrawn its June 2025 application for a CLIN2 clinical trial grant from the California Institute for Regenerative Medicine, which was intended to support continued development of its OPC1 cell therapy for spinal cord injuries. The withdrawal followed CIRM comments on the application received in late November 2025.
The company states that CIRM did not identify specific content deficiencies in the application and that, after discussions with CIRM representatives, it plans to submit a revised application in the next grant cycle currently scheduled for January 2026. Lineage also notes that this withdrawal and planned resubmission do not affect its current or planned OPC1 development work or the ongoing DOSED clinical study using a novel spinal cord delivery device in subacute and chronic spinal cord injury participants.
Lineage Cell Therapeutics announced that it has achieved the first development milestone under its collaboration and license agreement with Genentech and F. Hoffmann-La Roche for OpRegen, its lead cell therapy program for geographic atrophy secondary to age-related macular degeneration. Meeting this milestone on November 20, 2025, based on manufacturing and clinical progress in the Phase 2a GAlette trial, triggers a $5 million milestone payment to Lineage, expected within 30 days. Lineage reports that approximately 24.1% of this payment will be paid to the Israel Innovation Authority and 21.5% to Hadasit Medical Research and Development Ltd., under existing Israeli research and collaboration agreements tied to its subsidiary Cell Cure Neuroscience Ltd.